cervical primary tumors; adjacent normal cervical tissues; cervical squamous cell carcinoma tissues; paired adjacent nontumor cervical tissues; xenograft tumors
Ect1/E6E7; HeLa; C-33A; SiHa; ME-180; Caski
cell line-derived xenograft
ceRNA regulation (promotes); proliferation (promotes); cell cycle (promotes); migration (promotes); invasion (promotes); EMT (promotes); apoptosis (inhibits); glycolysis (promotes); metastasis (promotes)
RNase R Treatment; RT-qPCR; Clinical Sample Validation; Nuclear-Cytoplasmic Fractionation; Bioinformatics Analysis; Transfection; Colony Formation Assay; Cell Cycle Assay; Annexin V/PI Flow Cytometry; Transwell Assay; Western Blot; Luciferase Reporter Assay; RIP (RNA Immunoprecipitation); In Vivo Animal Model; IHC (Immunohistochemistry); ROC Analysis
circ_0084904 showed high diagnostic value in CC tissues compared with normal cervical tissues; silencing circ_0084904 might represent a promising targeted therapy for CC.
circ_0084904 is up-regulated in cervical cancer tissues and cell lines and functions as an oncogenic circRNA. It promotes malignant phenotypes including proliferation, cell cycle progression, migration, invasion, EMT, glycolysis, and tumor growth while suppressing apoptosis, mainly through the circ_0084904/miR-802/MAL2 regulatory axis. Its high diagnostic value and functional inhibition by silencing suggest potential clinical utility as a biomarker and therapeutic target.
0.8353
The novel circ_0084904/miR-802/MAL2 axis promotes the development of cervical cancer.
combined biological and clinical study